Stoll VS - Search Results

1

Kinetic mechanism and nucleotide specificity of NADH peroxidase.

Stoll VS, Blanchard JS. Stoll VS, et al. Arch Biochem Biophys. 1988 Feb 1;260(2):752-62. doi: 10.1016/0003-9861(88)90505-x. Arch Biochem Biophys. 1988. PMID: 3124762

2

Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.

Liu Y, Stoll VS, Richardson PL, Saldivar A, Klaus JL, Molla A, Kohlbrenner W, Kati WM. Liu Y, et al. Among authors: stoll vs. Arch Biochem Biophys. 2004 Jan 15;421(2):207-16. doi: 10.1016/j.abb.2003.11.013. Arch Biochem Biophys. 2004. PMID: 14984200

3

Chemical mechanism and rate-limiting steps in the reaction catalyzed by Streptococcus faecalis NADH peroxidase.

Stoll VS, Blanchard JS. Stoll VS, et al. Biochemistry. 1991 Jan 29;30(4):942-8. doi: 10.1021/bi00218a009. Biochemistry. 1991. PMID: 1899199

4

Crystallization and preliminary x-ray diffraction study of the flavoprotein NADH peroxidase from Streptococcus faecalis 10C1.

Schiering N, Stoll VS, Blanchard JS, Pai EF. Schiering N, et al. Among authors: stoll vs. J Biol Chem. 1989 Dec 15;264(35):21144-5. J Biol Chem. 1989. PMID: 2512289 Free article.

5

Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.

Stoll VS, Simpson SJ, Krauth-Siegel RL, Walsh CT, Pai EF. Stoll VS, et al. Biochemistry. 1997 May 27;36(21):6437-47. doi: 10.1021/bi963074p. Biochemistry. 1997. PMID: 9174360

6

Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes.

Stoll VS, Eger BT, Hynes RC, Martichonok V, Jones JB, Pai EF. Stoll VS, et al. Biochemistry. 1998 Jan 13;37(2):451-62. doi: 10.1021/bi971166o. Biochemistry. 1998. PMID: 9425066

7

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.

Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, Lin NH, Cohen J, Stoll VS, Jakob CG, Muchmore SW, Harlan JE, Holzman T, Walten KA, Ladror US, Anderson MG, Kroeger P, Rodriguez LE, Jarvis KP, Ferguson D, Marsh K, Ng S, Rosenberg SH, Sham HL, Zhang H. Gu WZ, et al. Among authors: stoll vs. Anticancer Drugs. 2005 Nov;16(10):1059-69. doi: 10.1097/00001813-200511000-00004. Anticancer Drugs. 2005. PMID: 16222147

8

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR. Dai Y, et al. Among authors: stoll vs. J Med Chem. 2005 Sep 22;48(19):6066-83. doi: 10.1021/jm050458h. J Med Chem. 2005. PMID: 16162008

9

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL. Luo Y, et al. Among authors: stoll vs. Mol Cancer Ther. 2005 Jun;4(6):977-86. doi: 10.1158/1535-7163.MCT-05-0005. Mol Cancer Ther. 2005. PMID: 15956255

10

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

Li Q, Wang GT, Li T, Gwaltney SL 2nd, Woods KW, Claiborne A, Wang X, Gu W, Cohen J, Stoll VS, Hutchins C, Frost D, Rosenberg SH, Sham HL. Li Q, et al. Among authors: stoll vs. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5371-6. doi: 10.1016/j.bmcl.2004.08.011. Bioorg Med Chem Lett. 2004. PMID: 15454229

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results